Osthole, a natural occurring coumarin, an ingredient of a Traditional Chinese Medicine, possesses a range of pharmacological and biochemical functions, including hepatoprotection, neuroprotection, anti-cancer, anti-osteoporosis, and anti-inflammatory properties. Recently, osthole has attracted intense research interest. Of great interest is the possibility that osthole could be a promising lead compound for exploiting new drugs for therapy of several diseases. These include insight into strong cytotoxic activity on cancer cells by causing apoptotic bodies, DNA fragmentation, enhancing human poly(ADP-ribose) polymerase (PARP) degradation, inhibition of proliferation by suppressing fatty acid synthase (FASN), protection of liver by increasing metabolism of lipases, prevention of hepatitis by inhibiting the Fas-mediated apoptotic pathway, induction of differentiation by increasing bone morphogenetic protein (BMP)-2 production and activating SMAD1/5/8, p38, extracellular signal-regualted kinase (ERK) 1/2, and Wnt/β-catenin signaling, neuroprotectioin by a mechanism of inhibiting ionic currents, including Na+ and Ca2+ channels. It is therefore useful to build up some correlations with the data available in order to better explore the molecular and cellular mechanism of osthole actions in the treatment of diseases. This review will focus on recent advances in molecular and cellular mechanism of osthole actions.
INTRODUCTION
Osthole, 7-methoxy-8-(3-methyl-2-butenyl) coumarin (Figure 1 ), a naturally occurring compound, is known to have a variety of pharmacological and biochemical uses and considered to have potential therapeutic applications [1] [2] . Osthole mainly exists in 14 species of Umbelliferae and 17 of Rutaceae. It has also been found to occur at a high percentage and be the effective compound in Cnidium monnier (L.) Cusson, which has been used in China for several hundred years as an herbal medicine to treat male sexual dysfunction by inhibiting phosphodiesterase type-5 (PDE-5), which degrades cyclic guanosine monophosphate (cGMP) that supports vasodilation to maintain rigidity by relaxing penile arteries and smooth muscle tissue [3] .
Due to unique structural features such as methoxyl at C-7 position and 3-methyl-2-butenyl at C-8 position, which are elucidated to be essential groups for activities [4] [5] , osthole displays a wide spectrum of pharmacological and biological functions. Osthole has been shown to exhibit anti-cancer [6] , anti-oxidant [1] , anti-inflammatory and immunomodulatory [7] [8] activities. It also has hepatoprotective [9] and neuroprotective [10] activities, suppresses postmenopausal osteoporosis [11] , and improves lipid metabolism [12] . Thus, osthole has received considerable attentions recently because of its diverse uses, which make it a very promising natural lead compound for new drugs discovery. 
Anti-cancer
Osthole has been shown to have cancer-preventive and cancer-fighting properties. Fujioka (1999) had screened the antiproliferative constituents from Umbelliferae plants and found that the antiproliferative activities (ED 50 , μg/ml) of osthole against human gastric adenocarcinoma (MK-1), human uterus carcinoma (HeLa), and murine melanoma (B16F10) cell lines in vitro were 82.7, 53.0, and 61.3, respectively [13] . Osthole (100 μM/L) showed a weak but significant antiproliferative activity against hormonoindependent PC3 and DU145 human prostate cell lines, 25.0% and 34.0% inhibition, respectively. However, osthole (100 μM/L) exhibited strong antiproliferative activity against mouse leukemia L1210 cell line with 65.4 ± 10.4% inhibition [14] . Antifibrotic activity of coumarins from Cnidium monnier fruits in hepatic stellate cells (HSC)-T6 had been screened. The results showed that osthole at a concentration of 100μM significantly inhibited proliferation of HSCs (cell viability was up to 31%) in a time-and concentration-dependent manner, which might be through the interference in cell proliferation not by cytotoxicity, and reduced collagen content to 24.5% [15] . Yang (2003) found that osthole exhibited strong cytotoxic activity on tumor cell lines, the IC 50 values on human leukemia (HL-60), P-388, HeLa, and colorectal carcinoma (CoLo 205) were 14.9, 9.3, 31.7, and 29.9 μg/ml after 24 hour treatment. Osthole also caused apoptotic bodies, DNA fragmentation, and enhanced PARP degradation in HL-60 cells. The structureactivity relationship studies indicated that the prenyl group had an important role in the cytotoxic effects [16] . The in vitro studies with osthole showed that it inhibited the growth of HeLa, in a time-and concentration-dependent manner, with IC 50 values of 77.96 and 64.94 μM after 24 and 48 h, respectively.
Osthole had lower cytotoxic effects in primary cultured normal cervical fibroblasts. Moreover, osthole could induce apoptosis in HeLa by increasing DNA fragmentation and activation of PARP. The in vivo model showed that the survival days of the P-388 D1 tumor-bearing CDF1 mice were prolonged (ILS% = 37) after osthole (30mg/kg) was given once a day for 9 days. Based on these results, it was suggested that osthole could inhibit P-388 D1 in vivo and induce apoptosis in HeLa cells in vitro [17] .
Recently, osthole has been reported to inhibit the migration and invasion of breast cancer cells (MCF-7 and MDA-MB 231 cell lines) by wound healing and transwell assays. Luciferase and zymography assays revealed that osthole effectively inhibited matrix metalloproteinase-2 (MMP-2) promoter and enzyme activity, which might be one of the causes that lead to the inhibition of migration and invasion by osthole [6] . While FASN has been shown to be expressed in many human solid tumors, FASN has also been identified in preneoplastic lesions. HER2 (alternatively known as neu or erbB2), which has also been identified in preneoplastic breast lesions, has been shown to upregulate FASN expression. Osthole was found to be effective in suppressing FASN expression, inhibit proliferation, and induce apoptosis in HER2-overexpressing breast cancer cells. Moreover, osthole inhibited the phosphorylation of Akt and mTOR. The use of Akt-overexpression revealed that the modulation of Akt and mTOR was required for osthole-induced FASN suppression [18] .
Histone deacetylases (HDACs) are reported to be important in chromatin remolding and regulation of gene expression. Therefore, HDACs inhibitors are regarded as promising therapeutics for the treatment of cancer. The structures of all HDAC inhibitors reported so far can be divided into three functional subunits, each of which interacts with a discrete region of the HDAC active site. The three subunits include: a zincbinding motif (such as hydroxamic acid), a hydrophobic cavity-binding linker with four to six carbon atoms, and a hydrophobic surface recognition cap that may confer class-specific recognition of the HDAC surface at the rim of the active-site cavity. Osthole is hydrophobic in nature with a ClogP value around 3.5 [19] . The hydrophobic nature of osthole is compatible with the chemical feature of the capping group in known HDAC inhibitors, which serves to form hydrophobic contact with the surface residues at the edge of the active site. Moreover, the branched aliphatic side chain in the chemical structure of osthole may be further exploited to provide specific interactions with different HDACs, which indicates that osthole could be a promising lead compound for anticancer drug [20] . 
Hepatoprotection
Alcohol is a major cause of fatty liver, which leads to inflammation, necrosis, fibrosis, and finally cirrhosis. There are currently no ideal pharmacological reagents that can prevent or reverse this disease. Osthole, however, appears to be a natural compound supported by several animal studies in regard to its liverprotective properties, including the prevention and treatment of fatty liver disease.
To evaluate the effects of osthole on fatty liver, a quail model with hyperlipidemic fatty liver and rat model with alcoholic fatty liver were set up by feeding high fat diet and alcohol, respectively. The results showed that after treatment with osthole the levels of serum total cholesterol (TC), triglyceride (TG), lower density lipoprotein-cholesterol (LDL-C), coefficient of hepatic weight, and the hepatic tissue contents of TC and TG were significantly decreased. The activity of superoxide dismutase (SOD) in liver was improved. In alcohol-induced fatty liver rats, the level of malondialdehyde (MDA) in liver was decreased. In high fat-induced fatty liver quails, glutathione peroxidase (GSH-PX) in liver was significantly improved. The histological evaluation of liver specimens demonstrated that the osthole dramatically decreased lipid accumulation [21] . A rat model with hyperlipidemic fatty liver liver was also successfully established. Similarly, the levels of rat serum TC, TG and LDL-C significantly were decreased as compared with those in the fatty liver model group after treatment with osthole [22] . In fatty milk-induced hyperlipidemic mice, the post-heparin plasma activities of lipoprotein lipase (LPL), hepatic lipase (HL), and total lipase (TL) were significantly increased after treatment with 10-20 mg/kg osthole for 3 weeks [22] . In addition, osthole could improve the insulin resistance induced by highfat and high-sucrose emulsion in fatty liver rats, and its mechanism might be associated with increment of adiponectin release via activation of PPAR α/γ pathway [23] .
To investigate the possible mechanism of osthole on the lipid-lowering effect, the BRL cells (rat hepatocyte line) were cultured and treated with osthole. The mRNA expressions of peroxisome proliferatoractivated receptor (PPAR) α and its related target gene cholesterol 7a-hydroxylase (CYP7A) were increased in dose dependent manner, whereas the mRNA expressions of the other two target genes diacylglycerol acyltransferase (DGAT) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase were decreased. However, these effects could be abrogated after pretreatment with specific inhibitor PPARα, MK886 [12] .
During screening of Chinese herbal medicines for the activities against hepatitis B virus (HBV), osthole was found to inhibit the secretion of HBV surface antigens (HBsAg) in vitro. The secretion of HBsAg in culture medium of MS-G2 and HuH-7 cells transfected with HBV DNA decreased by 60% to 70% after osthole treatment, without any detectable cytotoxic effects. Osthole suppresses the secretion of HBV in cell culture probably because of its novel function in increasing the glycosylation of HBsAg [24] .
Counteracting the effects of hepatitis C virus (HCV) through the use of coumarins has proved challenging as only a small number, primarily osthole, are capable of inhibiting HCV replication and/or proliferation, counteracting the progression of hepatitis C into hepatocarcinoma [25] . Studies with hepatitis model mice revealed that osthole could prevent hepatitis by inhibiting the development of apoptosis, which indicated that osthole had some possibilities to become a hepatoprotective drug candidate for a wide variety of liver diseases. Fas (Apo-1/CD95) ligand, which is a type Ⅱ membrane protein, is a major inducer of apoptosis. Administration of osthole to mice at a dose of 10 mg/kg significantly inhibited the anti-Fas antibody-induced elevation of plasma alanine aminotransferase (ALT). Treatment of mice with anti-Fas antibody caused an elevation of caspase-3 activity at 3.5 and 6 hr. Pretreatment of mice with osthole (100 mg/kg) inhibited the elevation of caspase-3 activity caused by anti-Fas antibody. However, the addition of osthole (up to 10 -4 M) to a liver cytosol fraction isolated from mice treatment with anti-Fas antibody did not inhibit caspase-3 activity in vitro. Thus, treatment of mice with osthole inhibited caspase-3 activity by an effect upstream of caspase-3 activation. Osthole attenuated the development of apoptosis and cell death; prevented anti-Fas antibodyinduced hepatitis by inhibiting the Fas-mediated apoptotic pathway [9] .
However, osthole exhibits low solubility in water and this property may lead to a decrease in the anti-hepatitis inhibitory effect upon oral administration. In a Con Ainduced hepatitis mouse model, intraperitoneally administered osthole (100 mg/kg dose) resulted in 85% inhibition of Con A-induced elevation of ALT. However, oral administration of osthole at a 100 mg/kg dose caused only a 38% inhibition of Con A-induced elevation of plasma ALT [26] . Osthenol, an osthole derivative with substitution of a 7-methoxy group for 7-hydroxy of osthole, caused 32% inhibition of Con Ainduced elevation of plasma ALT at the dose of 100 mg/kg (i.p.), whereas 7-HC caused only 9% inhibition [4] . These indicated that methoxy-group at position-7 and the 3-methyl-2-butenyl-group at position-8 are essential to lower plasma ALT in hepatitis.
Anti-osteoporosis
One of the most promising areas of potential benefits from the use of osthole clearly appears to be in the area of osteogenic (bone-building) activity. The compounds isolated from fruits of Cnidium monnieri (L.) Cuss (Umbelifera) were screened using the osteoblast-like UMR106 cells in vitro. Osthole, a major pharmacologically active constituent, significantly promoted the cells' activity [27] . To examine the effects of osthole on postmenopausal osteoporosis in ovariectomized (OVX) rat models, found that osthole might be just as effective as 17β-estradiol in suppressing bone loss due to ovariectomy but it perhaps did not work through the estrogen pathway [11] . In Traditional Chinese Medicine, the cause of weak bones or bone loss is generally regarded as a result of kidney deficiency. Osthole, the major effective compound of Fructus Cnidii which was a traditional herb that had been claimed to have kidney warming effects, was reported to be effective at inducing osteoblastic bone formation through the up-regulation of alkaline phosphatase (ALP) activity. Concentrations lower than 40 μg/mL, osthole seemed less effective, and cytotoxicity to osteoblasts was observed at concentrations higher that 320 μg/mL [28] .
The survival of osteoblast cells is one of the determinants of the development of osteoporosis. Osthole exhibited a significant induction of differentiation in two human osteoblast-like cell lines, human osteosarcoma cell line (MG-63) and human fetal osteoblastic cell line (hFOB). Induction of differentiation by osthole was associated with increased BMP-2 production and the activations of SMAD1/5/8 and p38 and ERK1/2. Addition of purified BMP-2 protein did not increase the up-regulation of ALP activity and osteocalcin by osthole, whereas the BMP-2 antagonist noggin blocked both osthole and BMP-2-mediated ALP activity enhancement, indicating that BMP-2 production was required in osthole-mediated osteoblast maturation. However, pretreatment of osteoblast cells with noggin abrogated p38 activation, and partially decreased ERK1/2 activation, suggesting that BMP-2 signaling was required in p38 activation, and was partially involved in ERK1/2 activation in osthole-treated osteoblast cells. Cotreatment with either p38 inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinyl-phenyl)-5-(4-pyridyl)-1H-imidazole] or p38 small interfering RNA (siRNA) expression inhibited osthole-mediated activation of ALP, but only slightly affected osteocalcin production. In contrast, the production of osteocalcin induced by osthole was inhibited by the mitogen activated protein kinase (MAPK) inhibitor PD98059 (2'-amino-3'-methoxyflavone) or by expression of an ERK2 siRNA. These data suggested that the BMP-2/p38 pathway linked to the early phase, whereas the ERK1/2 pathway was associated with the later phase in osthole-mediated differentiation of osteoblast cells [29] .
Osteoporosis is defined as reduced bone mineral density with a high risk of fragile fracture. Current available treatment regimens include antiresorptive drugs such as estrogen receptor analogues and bisphosphates and anabolic agents such as parathyroid hormone (PTH). However, neither option is completely satisfactory because of adverse effects. Local injection of osthole significantly increased new bone formation on the surface of mouse calvaria. Ovariectomy caused evident bone loss in rats, whereas osthole largely prevented such loss, improved bone microarchitecture, histomorphometric parameters, and biomechanical properties. In vitro studies demonstrated that osthole activated Wnt/β-catenin signaling, increased Bmp2 expression, and stimulated osteoblast differentiation. Targeted deletion of the β-catenin and Bmp2 genes abolished the stimulatory effect of osthole on osteoblast differentiation. Since deletion of the Bmp2 gene did not affect osthole-induced β-catenin expression and the deletion of the β-catenin gene inhibited ostholeregulated Bmp2 expression in osteoblasts. Thus, osthole might act through β-catenin-BMP signaling to promote osteoblast differentiation [30] .
Neuroprotection
Osthole could inhibit voltage-gated Na + currents with state-dependence in mouse neuroblastoma N2A cells (IC 50 = 12.3 mM and 31.5 mM at holding potentials of -70 mV and -100 mV, respectively). Current blockades were equally effective in both extracellular and intracellular applications of osthole. Osthole (18 mM) did not significantly affect the kinetics and voltage-dependence of Na + channel activation, but leftshifted the steady-state inactivation curve (V 1/2 = -60.5 mV and -78.7 mV in the absence and presence of osthole, respectively). Osthole also mildly but significantly retarded channel recovery from inactivation (recovery time constant = 19.9 ms and 35.6 ms in the absence and presence of osthole, respectively). In addition, osthole blocked Na + currents in a frequency-dependent fashion: blockades of 17 %, 34 % and 49 % when currents were triggered at 0.33 Hz, 1 Hz and 3.33 Hz, respectively. Taken together, osthole blocked voltage-gated Na + channels intracellularly with state-and frequency-dependence [31] .
The effects of osthole on ionic currents in a mouse neuroblastoma and rat glima hybrid cell line, NG105-18, were investigated with the aid of the whole-cell voltage-clam technique. Osthole (0.3-100 μM) caused an inhibition of voltage-dependent L-type Ca 2+ current (I Ca,L ) in a concentration-dependent manner. Osthole produced no change in the overall shape of the currentvoltage relationship of I Ca,L . The IC 50 value of the osthole-induced inhibition of I Ca,L was 4μM. The presence of osthole (3μM) shifted the steady state inactivation curve of I Ca,L to a more negative potential by approximately -15mV. Osthole (3μM) also produced a prolongation in the recovery of I Ca,L inactivation. Although osthole might suppress phosophodiesterases to increase intracellular adenosine-3',5'-cyclic monophosphate (cyclic AMP) or guanosine-3',5'-cyclic monophosphate (cyclic GMP), sp-cAMPS did not affect I Ca,L and 8-bromo-cyclic GMP slightly suppressed it. Thus, osthole-mediated inhibition of I Ca,L was not associated with intracellular cyclic AMP or GMP. However, no effect of osthole on voltagedependent K + outward current was observed [32] . Osthole significantly facilitated 4-aminopridine (4-AP)-evoked glutamate release in a concentration-dependent manner. The release facilitation by osthole results from an enhancement of vesicular exocytosis and not from an increase of Ca 2+ -independent efflux via glutamate transporter. Examination of the effect of osthole on cytosolic [Ca 2+ ] revealed that the facilitation of glutamate release could be attributed to an increase in voltage-dependent Ca 2+ influx. Consistent with this, ω-conotoxin MVIIC, a wide-spectrum blocker of the Nand P/Q-type Ca 2+ channels, significantly suppressed the osthole-mediated facilitation of glutamate release, but intracellular Ca 2+ release inhibitor dantrolene had no effect. Osthole did not alter the resting synaptosomal membrane potential or 4-AP-mediated depolarization; thus, the facilitation of 4-AP-evoked Ca 2+ influx and glutamate release produced by osthole was not due to it decreasing synaptosomal excitability. In addition, osthole increased 4-AP-induced phosphorylation of PKC. These suggested that osthole effects a facilitation of glutamate release from nerve terminals by positively modulating N-and P/Q-type Ca 2+ channel activation through a signaling cascade involving PKC [33] . Further investigation whether osthole possesses an action at the exocytotic machinery itself, downstream of a Ca 2+ influx, found that osthole-mediated facilitation of glutamate release involves modulation of downstream events controlling synaptic vesicle recruitment and exocytosis, possibly through an increase Ca 2+ /calmodulin-dependent kinase II (CaMK II) activation and synapsin I phosphorylation, thereby increasing synaptic vesicle availability for exocytosis [34] .
Considering the above-mentioned molecular mechanisms of action of osthole in preclinical studies, osthole was hypothesized to possess the antielectroshock action due to its effect on Ca 2+ channels. The mouse maximal electroshock induced seizure model was built. Time course of anticonvulsant action of osthole revealed that it, in a dose-dependent manner, produced a clear-cut antielectroshock activity in mice and the experimentally-derived ED 50 values for osthole ranged from 259 to 631 mg/kg [35] . Additionally, acute adverse-effect (neurotoxic) profile for osthole was determined in the chimney test. The results showed that the median toxic doses (TD 50 ) value ranged from 531 to 648 mg/kg. The protective index (as a ratio of TD 50 and ED 50 values) for osthole ranged from 0.83 to 2.44 [36] . Conclusively, osthole should deserve more attentions from a preclinical point of view as a compound possessing potentially favorable activities in terms of suppression of seizures.
The 1-methyl-4-phenylpyridinium ion (MPP + ), an inhibitor of mitochondrial complex I, has been widely used as a neurotoxin because it causes a severe Parkinson's disease-like syndrome accompanied by increased levels of intracellular reactive oxygen species (ROS) and apoptotic death. To investigate the protective effects of osthole on MPP + -induced cytotoxicity in cultured rat adrenal pheochromocytoma (PC12) cells, reported that pretreatment with osthole on PC12 cells significantly reduced the loss of cell viability, the release of lactate dehydrogenase, the activity of caspase-3 and cytochrome c, the increase in Bax/Bcl-2 ratio and the generation of intracellular ROS induced by MPP + . Moreover, the HPLC analysis of cell extracts confirmed that extracellular osthole did penetrate the cell membrane [10] .
Recently, the neuroprotective effect of osthole against acute ischemic stroke was evaluated by neurological deficit score (NDS), dry-wet weight and 2,3,5-triphenyltetrazolium chloride (TTC) staining. The contents of MDA and glutathione (GSH), activity of myeloperoxidase (MPO) and the level of interleukin (IL)-1β and IL-8 after middle cerebral artery occlusion (MCAO) in rats were detected to investigate its antioxidative action and anti-inflammatory property. Pretreatment with osthole significantly increased in GSH, and decreased the volume of infarction, NDS, edema, MDA, MPO, IL-1β and IL-8, which might suggest that the anti-oxidative action and antiinflammatory property of osthole contribute to a beneficial effect against stroke [37] . To investigate the effects of osthole on cognitive impairment and neuronal degeneration in hippocampus, models of occlusion of bilateral common carotid arteries (2VO) were established and found that osthole decreased the production of MDA, the ratio of bax/bcl-2, and the activation of caspase-3, and significantly increased the activities of glutathione peroxidase (GPx) and catalase. Additionally, oral administration of osthole for 3 weeks markedly attenuated cognitive deficits and neuronal damage [38] . The observed results suggested that osthole exhibits therapeutic potential for vascular dementia, which is most likely related, at least in part, to its anti-oxidation and anti-apoptotic actions.
Anti-inflammation
Osthole was tested in cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) bioassays and turned out to be a moderate and selective a 5-lipoxygenase inhibitor (IC 50 = 36.2 μM) [7] . In LPS-stimulated macrophages, osthole inhibited tumor necrosis factor-alpha (TNF-α), nitric oxide (NO) and COX-2 expression, without reducing the expression of IL-6. Furthermore, the phosphorylation of p38, c-Jun N-terminal kinase 1/2 (JNK1/2), protein kinase C (PKC)-α and PKC-ε induced by LPS was inhibited by osthole; however, the phosphorylation of ERK1/2 and PKC-δ was not reduced by osthole. Osthole also inhibited nuclear transcription factor kappa-B (NF-κB) activation and ROS release in LPS-stimulated macrophages [39] .
Osthole showed significant inhibitory effects on ear swelling after dinitrofluorobenzene (DNFB) challenge, which exhibited the anti-allergic activity of osthole [40] . Asthma is an allergic inflammatory disease of the airways. Eotaxin, an eosinophil-specific C-C chemokine, is a potent chemo-attractant involved in the mobilization of eosinophils into the airway after allergic stimulation. The ability of osthole to regulate cytokine-induced eotaxin expression in the human bronchial epithelial cell line BEAS-2B was investigated. The results showed that IL-4 and TNF-α significantly induced eotaxin expression in BEAS-2B cells, expression of eotaxin was suppressed by osthole (0.1-10μM) in a dose-dependent manner; osthole did not suppress IL-4-induced p38, ERK or JNK expresseion, but suppress IL-4-induced STAT6 in a dose-dependent manner. This suggested that osthole suppressed IL-4-induced eotaxin in BEAS-2B cells via inhibition of STAT6 expression [41] .
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model for the study of the effects of osthole on the CNS demyelination. The results showed that osthole retarded the disease process when the therapy was initiated at subclinical periods, attenuated the clinical severity of EAE mice when the therapy was initiated at both subclinical and clinical periods, ameliorated inflammation and demyelination and improved the outcomes of magnetic resonance imaging. In addition, osthole blocked the reduction of nerve growth factor (NGF) and suppressed interferon gamma (IFN-γ) increase in EAE mice [42] . 
Miscellaneous
PPARs are steroid transcription factors that affect the multiple target gene expressions involved in glucose metabolism and fatty acid storage [43] . Osthole significantly activated both PPARα and PPARγ in a dose-dependent manner based on the results of the transition transfection assay. The activation of PPARα and PPARγ by osthole also resulted in an increase in the expression of PPAR target genes such as PPAR itself, adipose fatty acid-binding protein 2, acyl-CoA synthetases, and carnitine palmitoyltransferase-1A [44] . Recent studies demonstrated that activated MAPK could phosphorylate and activate PPAR through agonist-independent manner [45] . osthole was able to increase the phosphorylation of MAPK and then activate MAPK. It was possible that osthole activated PPAR through agonist-independent and MAPKdependent pathway. In addition, in the model of obese diabetic C57BKS.Cg-m +/+ Lepr db /JNarl (db/db) mice, osthole was found to markedly reduce blood glucose level, which might be mediated through a PPARindependent pathway [44] .
Osthole also has been reported to possess antiarrhythmic activity. Osthole induced relaxation in endothelium-intact rings with a lower threshold concentration (< 10 µM) than in endothelium-disrupted rings (> 10 µM). In the presence of L-NAME (a nitric oxide synthase inhibitor) or ODQ (a soluble guanylyl cyclase inhibitor), relaxation induced by osthole in endothelium-intact rings was similar to that in endothelium-disrupted rings. Osthole-induced relaxation was not inhibited by SQ22536 (an adenylyl cyclase inhibitor). The endothelium-dependent relaxation of osthole was mediated through nitric oxide-cGMP signaling cascade [46] .
CONCLUSION
The information provided above demonstrated that osthole had a diverse range of pharmacological and biochemical functions, including anti-cancer, hepatoprotection, anti-osteoporosis, neuroprotection, and anti-inflammatory properties. Due to its unique structural feature, osthole becomes a good candidate for the generation of lead compounds. Numerous studies confirmed osthole's potential role in animal models, yet further study is required to confirm its function in humans. The development of osthole-related drugs is very challenging due to the agent's poor absorption and low bioavailability; studies are still in their early stage. However, based on the compound's multifunctional actions, it appears that osthole will emerge as a promising therapeutic drug for the treatment and prevention of various chronic diseases. 
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